TapewireFind a company

organization · Reporting owner

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s.

Disclosed activity across 1 company

Tapewire entity
162270
SEC CIK
0001682250

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Emmaus Life Sciences, Inc.MYND · Entity 20510% ownerOctober 08, 2018November 21, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Emmaus Life Sciences, Inc.

Report date October 08, 2018 · Filed November 21, 2018 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
COMMON STOCKSEC Table I · non-derivativeDirect1,056,474 Reported balance After 2018-10-08 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2018-10-08 · Grant · Acquired 144,000 · Balance 1,056,474

F1: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 08, 2018 Filed Nov 20, 2018 22:46 UTC Emmaus Life Sciences, Inc. MYND · Entity 205 GrantCOMMON STOCK 144,000 $1.38 $198,720.00
Disclosure

SEC source: 0001615774-18-013075 · s114146_form4.xml · nonDerivative · entry 1

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,056,474

F1 · kind: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

F1 · shares: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

F1 · acquired: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

Read SEC document
October 08, 2018 Filed Nov 21, 2018 21:50 UTC Amendment Emmaus Life Sciences, Inc. MYND · Entity 205 GrantCOMMON STOCK 144,000 $1.38 $198,720.00
Disclosure

SEC source: 0001615774-18-013143 · ownership.xml · nonDerivative · entry 1

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,056,474

F1 · kind: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

F1 · shares: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

F1 · acquired: On October 8, 2018, the Reporting Person acquired the 144,000 shares of restricted common stock because Michal Votruba immediately and automatically assigned all benefits resulting from an October 8, 2018 grant of restricted common stock to the Reporting Person pursuant to the policies of the Reporting Person regarding stock ownership by its employees, as documented by an Agreement between Michal Votruba and the Reporting Person. Michal Votruba was entitled to acquire the shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. Michal Votruba is serving on the Board of MYnd Analytics, Inc. at the request of the Reporting Person.

Read SEC document
October 03, 2018 Filed Oct 4, 2018 22:33 UTC Emmaus Life Sciences, Inc. MYND · Entity 205 GrantCommon Stock Purchase Warrant · Derivative 270,270 Not disclosed Strike: $2.00 Not disclosed
Disclosure

SEC source: 0001615774-18-010497 · s113137_form4.xml · derivative · entry 2

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,270

Underlying: Common Stock · 270,270 shares

Expires 2023-09-23

F2 · price: Reporting Person purchased 270,270 units at a price of $1.85 per unit, with each unit consisting of (i) one share of Common Stock and (ii) one Common Stock Purchase Warrant to purchase one share of Common Stock for $2.00 per share.

Read SEC document
October 03, 2018 Filed Oct 4, 2018 22:33 UTC Emmaus Life Sciences, Inc. MYND · Entity 205 GrantCOMMON STOCK 270,270 $1.85 $499,999.50
Disclosure

SEC source: 0001615774-18-010497 · s113137_form4.xml · nonDerivative · entry 1

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 912,474

F1 · security: 270,270 shares of Common Stock and Warrants to purchase 270,270 shares of Common Stock for $2.00 were purchased by the Reporting Person for an aggregate of $499,999.50 pursuant to a Subscription Agreement, dated September 21, 2018 (the "Subscription Agreement"), between the Issuer and the investors party thereto.

Read SEC document
May 25, 2018 Filed May 31, 2018 00:30 UTC Emmaus Life Sciences, Inc. MYND · Entity 205 GrantCommon Stock 4,500 $2.27 $10,215.00
Disclosure

SEC source: 0001615774-18-004584 · s110528_form4.xml · nonDerivative · entry 1

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 642,204

F1 · shares: On May 25, 2018, the Board of Directors (the "Board") of MYnd Analytics, Inc. granted the indicated number of restricted shares (the "Shares") in lieu of the remaining amount of Michal Votruba's Board fee for the 2017-2018 fiscal year. Mr. Votruba has agreed to assign all compensation provided for his service on the Board to the Reporting Person. The Shares were issued pursuant to the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan.

Read SEC document
September 19, 2017 Filed Sep 22, 2017 23:03 UTC Emmaus Life Sciences, Inc. MYND · Entity 205 GrantDirector Stock Option (right to buy) · Derivative 12,000 $0.00 Strike: $3.60 $0.00
Disclosure

SEC source: 0001615774-17-005313 · s107587_form4.xml · derivative · entry 2

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2027-09-19

F1 · derivative.exercise_date: The option vests in four equal quarterly installments beginning on December 19, 2017.

Read SEC document
September 19, 2017 Filed Sep 22, 2017 23:03 UTC Emmaus Life Sciences, Inc. MYND · Entity 205 GrantCommon Stock 12,000 $0.00 $0.00
Disclosure

SEC source: 0001615774-17-005313 · s107587_form4.xml · nonDerivative · entry 1

RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus podfond, RSJ Investment SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 637,704

Read SEC document
March 20, 2017 Filed Mar 23, 2017 01:19 UTC Emmaus Life Sciences, Inc. MYAN · Entity 205 PurchaseCommon Stock, par value $0.001 per share 160,000 $6.25 $1,000,000.00
Disclosure

SEC source: 0001615774-17-001188 · s105639_form4.xml · nonDerivative · entry 1

RSJ Investments SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,704

F1 · kind: Acquired by the Reporting Person in a private placement of securities by the Issuer.

Read SEC document
November 01, 2016 Filed Nov 3, 2016 21:28 UTC Emmaus Life Sciences, Inc. MYAN · Entity 205 OtherCommon Stock, par value $0.001 per share 20,000 $0.00 $0.00
Disclosure

SEC source: 0001615774-16-008017 · s104542_form4.xml · nonDerivative · entry 1

RSJ Investments SICAV a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 465,704

F1 · kind: The shares of common stock, par value $0.001 per share (the "Common Stock") of MYnd Analytics, Inc. (the "Issuer") were initially granted by the Issuer to Michal Votruba, a director of the Issuer and an employee of the Reporting Person. The grant was recommended by the Issuer's compensation committee and approved by the Issuer's board of directors on September 22, 2016 under the Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan"), subject to stockholder approval of the Plan, and was subsequently made on November 1, 2016 when the Issuer's stockholders approved the Plan. Upon grant on November 1, 2016, the shares were immediately assigned and issued directly to the Reporting Person for no consideration, pursuant to a binding verbal agreement between Mr. Votruba and the Reporting Person.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 OtherCommon Stock Warrant · Derivative 5,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 22

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000,000 shares

Expires 2016-09-19

F6 · derivative.exercise_price: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F9 · price: See Exhibit 99.2.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · balance_after: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 OtherCommon Stock Warrant · Derivative 15,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 21

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000,000

Underlying: Common Stock · 15,000,000 shares

Expires 2016-09-19

F6 · derivative.exercise_price: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F9 · price: See Exhibit 99.2.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · balance_after: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 OtherCommon Stock Warrant · Derivative 22,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 20

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000,000

Underlying: Common Stock · 22,000,000 shares

Expires 2016-09-19

F6 · derivative.exercise_price: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F9 · price: See Exhibit 99.2.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · balance_after: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Conversion5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.03 $250,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 19

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 10,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F8 · reported_value: The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · derivative.underlying_shares: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Conversion5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.03 $750,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 18

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 30,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F8 · reported_value: The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · derivative.underlying_shares: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Conversion5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.03 $350,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 17

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 12,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F8 · reported_value: The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · derivative.underlying_shares: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Conversion5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.03 $750,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 16

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 30,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F8 · reported_value: The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · derivative.underlying_shares: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F6 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 PurchaseCommon Stock Warrant · Derivative 5,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 15

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000,000

Underlying: Common Stock · 5,000,000 shares

Expires not disclosed

F9 · price: See Exhibit 99.2.

F9 · derivative.expiration_date: See Exhibit 99.2.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 PurchaseCommon Stock Warrant · Derivative 15,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 14

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000,000

Underlying: Common Stock · 15,000,000 shares

Expires not disclosed

F9 · price: See Exhibit 99.2.

F9 · derivative.expiration_date: See Exhibit 99.2.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 PurchaseCommon Stock Warrant · Derivative 22,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 13

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000,000

Underlying: Common Stock · 22,000,000 shares

Expires not disclosed

F9 · price: See Exhibit 99.2.

F9 · derivative.expiration_date: See Exhibit 99.2.

F8 · balance_after: The number of derivative securities disposed does not include interest accrued at 5% per annum on the Notes. At the time that the Mandatory Conversion took effect, a total of $122,268.84 in interest had accrued on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 OtherCommon Stock Warrant · Derivative 5,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 12

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000,000 shares

Expires not disclosed

F9 · price: See Exhibit 99.2.

F9 · derivative.expiration_date: See Exhibit 99.2.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 OtherCommon Stock Warrant · Derivative 15,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 11

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000,000

Underlying: Common Stock · 15,000,000 shares

Expires not disclosed

F9 · price: See Exhibit 99.2.

F9 · derivative.expiration_date: See Exhibit 99.2.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 OtherCommon Stock Warrant · Derivative 22,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 10

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000,000

Underlying: Common Stock · 22,000,000 shares

Expires not disclosed

F9 · price: See Exhibit 99.2.

F9 · derivative.expiration_date: See Exhibit 99.2.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Purchase5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed $250,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 9

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2017-12-31

F5 · derivative.exercise_price: See Exhibit 99.1.

F5 · reported_value: See Exhibit 99.1.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Purchase5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed $750,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 8

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2017-12-31

F5 · derivative.exercise_price: See Exhibit 99.1.

F5 · reported_value: See Exhibit 99.1.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Purchase5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed $350,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 7

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2017-12-31

F5 · derivative.exercise_price: See Exhibit 99.1.

F5 · reported_value: See Exhibit 99.1.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Purchase5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed $750,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 6

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2017-12-31

F5 · derivative.exercise_price: See Exhibit 99.1.

F5 · reported_value: See Exhibit 99.1.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Other5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.05 $250,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 5

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 5,000,000 shares

Expires 2017-12-31

F4 · security: The 5% secured convertible notes in the amounts of $750,000 and $250,000, the amendments of which are reported in this Form 4, were initially issued by the Issuer on December 28, 2015 and August 9, 2016, respectively. As previously reported, on December 28, 2015, the Issuer issued the 5% secured convertible promissory notes in the amount of $750,000 pursuant to the Second Amended and Restated Note Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein as later amended (the "A&R Note & Warrant Agreement"). Additionally, on August 9, 2016, the Issuer issued the 5% secured convertible promissory notes in the amount of $250,000 under the A&R Note Warrant Agreement.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Other5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.05 $750,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 4

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 15,000,000 shares

Expires 2017-12-31

F4 · security: The 5% secured convertible notes in the amounts of $750,000 and $250,000, the amendments of which are reported in this Form 4, were initially issued by the Issuer on December 28, 2015 and August 9, 2016, respectively. As previously reported, on December 28, 2015, the Issuer issued the 5% secured convertible promissory notes in the amount of $750,000 pursuant to the Second Amended and Restated Note Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein as later amended (the "A&R Note & Warrant Agreement"). Additionally, on August 9, 2016, the Issuer issued the 5% secured convertible promissory notes in the amount of $250,000 under the A&R Note Warrant Agreement.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Other5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.05 $350,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 3

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 7,000,000 shares

Expires 2017-12-31

F3 · security: The 5% secured convertible notes in the amount of $350,000, the amendment of which is reported in this Form 4, were initially issued by the Issuer on September 24, 2015.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Other5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.05 $750,000.00
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · derivative · entry 2

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 15,000,000 shares

Expires 2017-12-31

F2 · security: The 5% secured convertible notes in the amount of $750,000, the amendment of which is reported in this Form 4, were initially issued by the Issuer on September 26, 2014.

F5 · price: See Exhibit 99.1.

F5 · derivative.exercise_date: See Exhibit 99.1.

F6 · derivative.expiration_date: Pursuant to the A&R Note & Warrant Agreement, as amended by the Second Amendment, on September 19, 2016, the Issuer effected a Mandatory Conversion with respect to all outstanding Notes held by the Reporting Person. The Mandatory Conversion had the effect of (i) converting each $0.025 of Notes into a share of common stock, with any resulting fraction of a share being rounded to the nearest whole share (with 0.5 being rounded up) and (ii) causing all warrants to be automatically cancelled, to be of no further legal force or effect and to be no longer exercisable for any shares of Common Stock.

F5 · derivative.underlying_shares: See Exhibit 99.1.

F7 · valueOwnedAfter: Pursuant to the A&R Note & Warrant Agreement, all Notes earn interest at a rate of 5% per annum with interest payable at maturity, which is set at December 31, 2017 (subject to earlier conversion or prepayment). The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document
September 19, 2016 Filed Sep 23, 2016 20:52 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 ConversionCommon Stock, par value $0.001 per share 444,454 Not disclosed Not disclosed
Disclosure

SEC source: 0001615774-16-007343 · s104203_form4.xml · nonDerivative · entry 1

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 445,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On September 19, 2016, MYnd Analytics, Inc. (the "Issuer") effected a Mandatory Conversion (as defined below) with respect to all outstanding Notes (as defined below) held by the Reporting Person. The Mandatory Conversion had the effect of converting each $0.025 of principal and accrued interest held by the Reporting Person, a total of $2,222,268.84 in outstanding Notes, into one share of Common Stock. On September 21, 2016, the Issuer completed a 200-to-1 reverse stock split. The amount stated represents the post-split adjusted amount. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share (with 0.5 being rounded up).

F1 · price: On September 19, 2016, MYnd Analytics, Inc. (the "Issuer") effected a Mandatory Conversion (as defined below) with respect to all outstanding Notes (as defined below) held by the Reporting Person. The Mandatory Conversion had the effect of converting each $0.025 of principal and accrued interest held by the Reporting Person, a total of $2,222,268.84 in outstanding Notes, into one share of Common Stock. On September 21, 2016, the Issuer completed a 200-to-1 reverse stock split. The amount stated represents the post-split adjusted amount. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share (with 0.5 being rounded up).

F1 · balance_after: On September 19, 2016, MYnd Analytics, Inc. (the "Issuer") effected a Mandatory Conversion (as defined below) with respect to all outstanding Notes (as defined below) held by the Reporting Person. The Mandatory Conversion had the effect of converting each $0.025 of principal and accrued interest held by the Reporting Person, a total of $2,222,268.84 in outstanding Notes, into one share of Common Stock. On September 21, 2016, the Issuer completed a 200-to-1 reverse stock split. The amount stated represents the post-split adjusted amount. Fractional shares resulting from the reverse stock split were rounded to the nearest whole share (with 0.5 being rounded up).

Read SEC document
August 09, 2016 Filed Sep 15, 2016 20:27 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 PurchaseCommon Stock Warrant · Derivative 5,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007204 · s104129_form4.xml · derivative · entry 5

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000,000

Underlying: Common Stock · 5,000,000 shares

Expires 2020-12-31

F8 · price: The Notes and warrant to purchase shares of Common Stock were issued in exchange for $250,000 in cash pursuant to the A&R Note & Warrant Agreement.

F5 · derivative.expiration_date: The expiration date of the warrants to purchase shares of Common Stock is the earlier of (i) December 31, 2020 and (ii) the date that is 45 days following the date on which the daily closing price of the Issuer's shares of Common Stock listed on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Issuer's Common Stock is traded or listed) exceeds $0.25 for at least ten consecutive trading days.

Read SEC document
August 09, 2016 Filed Sep 15, 2016 20:27 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Purchase5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.05 $250,000.00
Disclosure

SEC source: 0001615774-16-007204 · s104129_form4.xml · derivative · entry 4

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 5,000,000 shares

Expires 2017-12-31

F2 · security: The 5% secured convertible promissory notes (the "Notes") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the "A&R Note & Warrant Agreement"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and certain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity.

F3 · reported_value: The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock.

F8 · price: The Notes and warrant to purchase shares of Common Stock were issued in exchange for $250,000 in cash pursuant to the A&R Note & Warrant Agreement.

F4 · derivative.exercise_date: The Notes are convertible into shares of Common Stock (i) automatically upon the closing of a qualified equity offering with total proceeds of at least $5 million, at a conversion price of $0.05 per share, or (ii) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share.

F2 · derivative.expiration_date: The 5% secured convertible promissory notes (the "Notes") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the "A&R Note & Warrant Agreement"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and certain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity.

F3 · derivative.underlying_shares: The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock.

F7 · valueOwnedAfter: The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

F9 · valueOwnedAfter: As of September 15, 2016, consists of Notes in aggregate principal amounts of $750,000 issued on September 26, 2014, $350,000 issued on September 24, 2015, $750,000 issued on December 28, 2015 and $250,000 issued on August 9, 2016.

Read SEC document
April 05, 2016 Filed Sep 15, 2016 20:27 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 OtherCommon Stock, par value $0.001 per share 250,000 $0.00 $0.00
Disclosure

SEC source: 0001615774-16-007204 · s104129_form4.xml · nonDerivative · entry 1

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

F1 · kind: The shares of common stock, par value $0.001 per share (the "Common Stock") of MYnd Analytics, Inc. (the "Issuer") were granted by the Issuer to Michal Votruba, a director of the Issuer and an employee of Reporting Person, on April 5, 2016. Upon grant, the shares were immediately assigned to the Reporting Person for no consideration, pursuant to a binding verbal agreement between Mr. Votruba and the Reporting Person.

Read SEC document
December 28, 2015 Filed Sep 15, 2016 20:27 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 PurchaseCommon Stock Warrant · Derivative 15,000,000 Not disclosed Strike: $0.05 Not disclosed
Disclosure

SEC source: 0001615774-16-007204 · s104129_form4.xml · derivative · entry 3

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000,000

Underlying: Common Stock · 15,000,000 shares

Expires 2020-12-31

F6 · price: The Notes and warrant to purchase shares of Common Stock were issued in exchange for $750,000 in cash pursuant to the A&R Note & Warrant Agreement.

F5 · derivative.expiration_date: The expiration date of the warrants to purchase shares of Common Stock is the earlier of (i) December 31, 2020 and (ii) the date that is 45 days following the date on which the daily closing price of the Issuer's shares of Common Stock listed on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Issuer's Common Stock is traded or listed) exceeds $0.25 for at least ten consecutive trading days.

Read SEC document
December 28, 2015 Filed Sep 15, 2016 20:27 UTC Emmaus Life Sciences, Inc. CNSO · Entity 205 Purchase5% Secured Convertible Note due December 2017 · Derivative Not disclosed Not disclosed Strike: $0.05 $750,000.00
Disclosure

SEC source: 0001615774-16-007204 · s104129_form4.xml · derivative · entry 2

RSJ Private Equity Investment Fund with variable registered capital, a.s. · CIK 0001682250 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 15,000,000 shares

Expires 2017-12-31

F2 · security: The 5% secured convertible promissory notes (the "Notes") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the "A&R Note & Warrant Agreement"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and certain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity.

F3 · reported_value: The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock.

F6 · price: The Notes and warrant to purchase shares of Common Stock were issued in exchange for $750,000 in cash pursuant to the A&R Note & Warrant Agreement.

F4 · derivative.exercise_date: The Notes are convertible into shares of Common Stock (i) automatically upon the closing of a qualified equity offering with total proceeds of at least $5 million, at a conversion price of $0.05 per share, or (ii) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share.

F2 · derivative.expiration_date: The 5% secured convertible promissory notes (the "Notes") were issued pursuant to the Second Amended and Restated Note & Warrant Purchase Agreement, dated December 23, 2015, between the Issuer, the Reporting Person and certain other investors named therein, as later amended by Amendment No. 1 thereto, dated August 15, 2016 (the "A&R Note & Warrant Agreement"). The A&R Note & Warrant Agreement also amended previous note purchase agreements among the Issuer, the Reporting Person and certain other investors named therein. The Notes mature on December 31, 2017 (subject to earlier conversion or prepayment) and earn interest at a rate of 5% per annum with interest payable at maturity.

F3 · derivative.underlying_shares: The Notes are convertible into shares of Common Stock of the Issuer at a conversion rate of $0.05 per share of Common Stock.

F7 · valueOwnedAfter: The number of derivative securities beneficially owned does not include interest accrued at 5% per annum on the Notes.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.